Suppr超能文献

用于抗癌化合物体外筛选的半自动比色测定法。

Semiautomated colorimetric assay for in vitro screening of anticancer compounds.

作者信息

Ruben R L, Neubauer R H

机构信息

Medical Products Department, E.I. Du Pont de Nemours and Company, Glenolden, PA 19036.

出版信息

Cancer Treat Rep. 1987 Dec;71(12):1141-9.

PMID:3690523
Abstract

An in vitro tetrazolium dye (MTT) reduction technique was modified and evaluated for use in the large-scale screening of anticancer compounds by examining the activity of ten clinically used drugs against 16 different human and murine cell populations. Cell populations included colon and mammary adenocarcinomas, melanomas, leukemias, and freshly isolated normal cells. Cell lines were grown in microtiter plates for 18-20 hours prior to a 72-hour continuous exposure to the drugs. Cultures were initiated at cell densities which maximized both the difference in dye reduction and the number of cell doublings between the beginning and end of the drug exposure period. Drug potency, expressed as the 50% inhibitory concentration (IC50), was comparable whether the effect on cell doublings or dye reduction was determined. There was good agreement between this method and the more labor-intensive, conventional method of counting trypan blue dye-excluding cells in a hemacytometer. Implemented as a large-scale, high-capacity system, our adaptation of the MTT technique is a rapid, sensitive, reproducible first-line screening device for detecting anticancer compounds with cytostatic or cytocidal activity.

摘要

通过检测十种临床使用的药物对16种不同人类和小鼠细胞群体的活性,对体外四氮唑染料(MTT)还原技术进行了改进和评估,以用于抗癌化合物的大规模筛选。细胞群体包括结肠和乳腺腺癌、黑色素瘤、白血病以及新鲜分离的正常细胞。细胞系在微量滴定板中培养18 - 20小时,然后连续72小时暴露于药物。培养物起始的细胞密度要使染料还原差异以及药物暴露期开始和结束之间的细胞倍增数最大化。以50%抑制浓度(IC50)表示的药物效力,无论通过测定对细胞倍增还是染料还原的影响来确定,都是相当的。该方法与在血细胞计数器中计数台盼蓝拒染细胞这种更耗费人力的传统方法之间具有良好的一致性。作为一种大规模、高容量的系统实施,我们对MTT技术的改进是一种用于检测具有细胞生长抑制或细胞杀伤活性的抗癌化合物的快速、灵敏、可重复的一线筛选装置。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验